NEW YORK--(BUSINESS WIRE)--Hildred Capital Management, LLC (“Hildred”), a New York based private equity firm focused on healthcare, today announced that Orle Mulamekic has been appointed Managing Director and Chief Financial Officer. Mr. Mulamekic brings nearly two decades of financial operations experience in private equity, including deep expertise in fundraising, financial reporting, tax, investor relations and portfolio company valuation.
“Orle is a seasoned financial professional who will help support Hildred’s continued growth as a firm,” said Managing Partners David Solomon and Andrew Goldman. “Orle has a proven track record of providing strategic, financial and operational leadership at both the fund and portfolio company level, and he will be a key member of the team, developing the infrastructure needed as we become a larger fund. We are confident that his extensive expertise will benefit both Hildred and our valued partners, and we are thrilled to welcome him to the firm.”
“I’m grateful for the opportunity to join Hildred’s management team, which has truly unique investment and operational experience in the healthcare sector,” said Orle Mulamekic, Managing Director and Chief Financial Officer at Hildred Capital Management. “Healthcare is an incredibly attractive and rapidly evolving area, and I look forward to working with David, Andrew and the rest of the team at Hildred as we pursue opportunities that build on Hildred’s enviable track record of generating strong returns for investors while improving patient outcomes, expanding access to high quality care and reducing costs.”
Mr. Mulamekic joins Hildred from Rhône Group, a transatlantic middle market private equity firm, where he most recently served as Chief Financial Officer of Global Funds overseeing four active funds with commitments of approximately $7 billion and AUM of approximately $10 billion. During his 15 year tenure at Rhône Group, Mr. Mulamekic’s responsibilities included all aspects of fund and management company accounting, tax, controls, analysis, planning and decision support to enhance performance and growth. Mr. Mulamekic was instrumental in the successful fundraising of Rhône Group’s Fund IV, which closed with $1.65 billion in commitments, Fund V, which closed with $2.9 billion in commitments, and Fund VI, which closed with $2.4 billion in commitments.
Prior to Rhône Group, Mr. Mulamekic was a Financial Services Manager at Deloitte, where he performed audits of private investment entities and worked closely with senior management teams to advise on external financial statements and valuations.
Mr. Mulamekic earned his BBA in Management from Berkeley College and his MBA from Baruch College.
Hildred is a New York-based private equity investment firm that pursues growth equity investments in middle market healthcare companies with leading products, technologies, and services. Hildred invests in companies with revenues of up to $100 million and creates value from pursuing organic growth strategies, driving effective resource allocation, implementing operational improvements, generating business development, and supporting best-in-class management teams. Areas with attractive fundamentals where Hildred may invest include the following healthcare subsectors: healthcare services, consumer products, information technology, medical devices, life science tools and diagnostics, healthcare related development and manufacturing, and pharmaceuticals, as well as related businesses that impact these healthcare subsectors. For more information, please visit www.hildredcapital.com.
Hugh Burns/Pamela Greene